Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 275

Archive for the ‘Estero/world news’ Category

world news

Due mesi di paura e stenti nella provincia di Ituri, in RDC

Posted by fidest press agency su martedì, 20 agosto 2019

A due mesi dalle violenze che hanno costretto centinaia di migliaia di persone a fuggire dalle loro case nella provincia orientale di Ituri, nella Repubblica Democratica del Congo, un grave sottofinanziamento e la crescente insicurezza hanno reso un numero crescente di persone bisognose di assistenza umanitaria e hanno impedito il loro ritorno a casa.
Nelle ultime tre settimane di giugno soltanto, oltre 145.000 persone costrette a fuggire di recente hanno cercato sicurezza e assistenza nei campi per sfollati interni e rifugiati nella provincia di Ituri, mentre si stima che altre 215.000 persone siano fuggite in aree vicine. I numeri reali sono difficili da verificare, a causa delle difficoltà di accesso in alcuni luoghi e dell’ampia area da cui le persone sono fuggite. In migliaia hanno continuato a fuggire da allora, anche se con minore frequenza.A causa della continua violenza tra gruppi armati, molti hanno paura di fare ritorno a casa. Durante una recente missione nella città di Djugu per fornire assistenza, lo staff dell’UNHCR, l’Agenzia delle Nazioni Unite per i Rifugiati, ha trovato un villaggio vuoto dopo l’altro e innumerevoli case date alle fiamme e abbandonate.Le persone sono state costrette a trovare un rifugio ovunque ne avessero la possibilità. Alcune sono state accolte da altre famiglie. Molte sono state costrette a dormire all’aperto. Drodro, una città relativamente piccola, ha visto la sua popolazione triplicarsi in sole poche settimane, mentre le scuole locali e le chiese sono state trasformate in grandi, squallidi dormitori.Il nostro staff ha raccolto numerose testimonianze di persone che hanno perso i loro familiari. Alcune persone che avevano tentato di rientrare a casa per prendere cibo e beni di proprietà sono state uccise da gruppi armati come avvertimento agli altri di non tornare. E’ stata riscontrata una prevalente paura per il futuro.I bisogni più urgenti riguardano l’alloggio, l’acqua, i servizi igienici, le cure sanitarie e il cibo. A causa delle condizioni di sovraffollamento, le donne e le bambine sono ad alto rischio di violenza sessuale e di genere. Le scarse condizioni igieniche, dovute alla mancanza di acqua pulita e di latrine, aumentano il rischio della diffusione delle malattie.L’UNHCR sta fornendo assistenza nei campi per sfollati interni, dove sta costruendo capannoni collettivi di emergenza per le persone costrette a dormire all’aperto, e rifugi individuali per le famiglie più vulnerabili. Tuttavia, occorrono urgentemente dei rifugi nuovi per permettere di liberare le scuole prima che cominci il nuovo semestre all’inizio di settembre. Vengono forniti i beni domestici essenziali, ma il bisogno è di gran lunga superiore alle scorte attuali dell’UNHCR.I finanziamenti per questa crisi umanitaria rimangono ad un livello criticamente basso. L’UNHCR fa appello alla comunità internazionale di farsi avanti con ulteriori fondi e permettere alle organizzazioni umanitarie di fornire un’assistenza salvavita di base. Finora nel 2019 l’UNHCR ha ricevuto solo il 32% dei 150 milioni di dollari statunitensi richiesti per le sue operazioni.

Posted in Estero/world news, Welfare/ Environment | Contrassegnato da tag: , , , | Leave a Comment »

AM Best Places Credit Ratings of The Guarantee Company of North America

Posted by fidest press agency su martedì, 20 agosto 2019

AM Best has placed under review with positive implications the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of “a” of The Guarantee Company of North America (Toronto, Ontario, Canada) and its subsidiary, The Guarantee Company of North America USA (Southfield, MI), collectively referred to as the Guarantee Companies. These companies are wholly owned subsidiaries of Princeton Holdings Limited.
The Credit Rating (rating) actions follow the announcement that Intact Financial Corporation (Intact) has entered into an agreement to acquire the Guarantee Companies from Princeton Holdings Limited. The transaction is subject to customary closing conditions, including regulatory approvals in the United States and Canada, and is expected to close in the fourth quarter of 2019.The under review with positive implications status reflects the need for AM Best to further and fully assess the financial and operational impacts of the acquisition. In addition, the positive implications considers the successful track record that Intact has established with similar transactions in the past, and the benefits of operational synergies with Intact and its subsidiary companies. AM Best will continue to hold discussions with Intact and Guarantee Companies’ management and monitor the Guarantee Companies’ balance sheet strength, operating performance, business profile and enterprise risk management through the close of the transaction.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Canadian Technology Company Uses UltiPro to Manage Global Workforce

Posted by fidest press agency su martedì, 20 agosto 2019

Ultimate Software, a leading global provider of human capital management (HCM) and employee experience solutions in the cloud, announced today that Pivot Technology Solutions, a full-service information technology provider, is using UltiPro to more effectively manage its human capital globally.Pivot is an industry-leading information technology services and solutions provider to many of the world’s most successful companies, including members of the Fortune 1000, as well as governments and educational institutions. The Toronto, Canada-based company has a significant presence in the United States, including in California, Georgia, and Texas, and employees in Ireland who oversee Pivot’s hardware-purchasing system for customers. The company launched UltiPro in 2012, and optimized its use of solution to facilitate the company’s global growth.“We are driving value on multiple levels by using UltiPro as our single source for employee data globally,” said Kim Larrimore, HRIS/payroll manager at Pivot. “Our Finance department has visibility into our entire enterprise, and we can create detailed financial reports related to global labor costs without having to merge separate data files. From an HR perspective, we have one system for all employee records, so we can quickly and accurately answer a question from an employee contacting us from anywhere in the world. In addition, we recently rolled out UltiPro Recruiting and UltiPro Onboarding worldwide so new hires are added electronically to the solution, regardless of location. For employees, everyone has the same people-centric, user-friendly experience—to access their HR information, view pay data, and manage benefits.” According to Larrimore, UltiPro’s unifying experience is especially critical for Pivot, not only because of the company’s international presence, but also because of the way workers are spread geographically within each country.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Sheij Zakzaky regresa a su país al negársele tratamiento médico en la India

Posted by fidest press agency su martedì, 20 agosto 2019

El clérigo musulmán shií nigeriano Sheij Ibrahim al Zakzaky y su esposa regresarán a su país desde la India, donde viajaron con la vana esperanza de recibir tratamiento médico por las lesiones que habían recibido durante una brutal represión en su país.“Sheij Zakazky y Mallimah Zinat han declarado que regresarán a Nigeria en lugar de seguir siendo acosados y después de haberles sido negada la atención médica que requieren en la India”, informó el jueves la Comisión Islámica de Derechos Humanos (IHRC), con sede en Londres.La pareja dijo que Nueva Delhi les impidió contactar con su propio equipo médico, abogados, partidarios e incluso amigos a pedido del gobierno de Abuja.La casa del clérigo de 66 años, que es el líder del Movimiento Islámico en Nigeria (MIN), fue allanada en 2015 después de que el gobierno nigeriano alegara que sus partidarios habían bloqueado un convoy del ministro de Defensa del país. El movimiento rechazó categóricamente la acusación.Durante la redada, fue golpeado y perdió su ojo izquierdo. Su esposa sufrió heridas graves y tres de sus hijos y más de 300 de sus seguidores fueron asesinados.La pareja fue puesta bajo custodia después. Un tribunal nigeriano otorgó la fianza al clérigo musulmán la semana pasada para que pudiera volar a India para recibir tratamiento. Fueron escoltados al aeropuerto en medio de medidas de máxima seguridad.“Las acciones de las autoridades indias para facilitar el hostigamiento de la pareja a manos de los servicios de seguridad de Nigeria son extraordinarias”, agregó.Por su parte, fuentes del MIN dijeron que los agentes de seguridad nigerianos estaban coludiendo con agentes de seguridad extranjeros, que se cree que trabajan para el gobierno de EEUU.El MIN citó además a una fuente que dijo que antes de la llegada del jeque Zakzaky al Hospital Madenta de Nueva Delhi, funcionarios de la Embajada de EEUU en India habían “amenazado” a la gerencia del hospital para que no admitiera al clérigo. “Incluso cuando los médicos esperaban con entusiasmo recibir al Sheij para salvar su vida, agentes secretos estadounidenses amenazaron a los funcionarios del hospital para que no siguieran adelante con el tratamiento del Sheij en el hospital”, dijo el MIN. (by Libero.it)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ThalesNano Introduces MicroCube

Posted by fidest press agency su martedì, 20 agosto 2019

BUDAPEST, Hungary and SAN DIEGO (GLOBE NEWSWIRE)ThalesNano Inc. (www.thalesnano.com) announced that MicroCube™ and the PhotoCube™ series are to be launched at the 258th American Chemical Society National Meeting & Exposition (booth #2218) on the 25th of August 2019 in San Diego, California.The MicroCube™ system is the first compact, handheld instrument designed for chemical route-scouting and receiving instant feedback on reaction success. Fast and efficient processes on microgram scale are now available within minutes, from room temperature to 130°C and from atmospheric pressure to 50 bar. The innovative design enables performance of sensitive reactions without the use of gloveboxes. The instrument exploits the advantages of ThalesNano’s CatCart® technology, allowing safe and easy gas-liquid or gas-liquid-solid phase catalytic reactions, with the use of 12-50 mg catalyst amounts.Gergely Darvas, CEO of ThalesNano, commented: “We are proud to launch the MicroCube™, a cutting edge new instrument for repeated 0.1-2 milligram samples’ synthesis. The system works in a similar fashion to an automatic pipette and opens up solutions unprecedented on the market.”
The PhotoCube™ Series are the first professional photoreactors in the world, that are available as a self-assembly kit as well. Various configurations tailored to the customer’s needs can be applied to a diverse set of batch, flow, stop-flow and CSTR photochemical reactions. Options for multicolor and UV LEDs enable the users to apply up to 7+1 wavelengths even simultaneously and to cover a wide range of chemical applications.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

The “Europe Neurostimulation Market – Growth, Trends, and Forecast (2019 – 2024)”

Posted by fidest press agency su martedì, 20 agosto 2019

The major factors for the growth of the Europe neurostimulation market include the increase in geriatric population and rising prevalence of neurological disorders, rising demand for minimally invasive surgeries, and technological advancement.Among the age-related neurodegenerative disorders, Parkinson’s disease (PD) is the second most common, after Alzheimer’s disease. An estimated 10 million people are affected by this disease, globally. According to NHS UK, Parkinson’s disease is found affecting around 1 in 500 people, which means there are an estimated 127,000 people in the UK with the condition.Most people with Parkinson’s start to develop symptoms when they’re over 50, although around 1 in 20 people with the condition first experience symptoms when they’re under 40. Furthermore, neurostimulation devices also play a significant role in pain management.Recently in November 2018, Abbott announced the launch of the new DRG Invisible Trial System, which is approved by the United States Food and Drug Administration (FDA) and received CE Mark in Europe.Thus, owing to the rising prevalence of neurological diseases and increasing technological advancements the market is expected to witness high growth over the forecast period.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Indian Artificial Intelligence

Posted by fidest press agency su martedì, 20 agosto 2019

The “India Artificial Intelligence (AI) Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024” report has been added to ResearchAndMarkets.com’s offering.
The country research report on India artificial intelligence (AI) market is a customer intelligence and competitive study of the India market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the India market. Also, factors that are driving and restraining the artificial intelligence (AI) market are highlighted in the study.This is an in-depth business intelligence report based on qualitative and quantitative parameters of the market. Additionally, this report provides readers with market insights and detailed analysis of market segments to possible micro levels. The companies and dealers/distributors profiled in the report include manufacturers & suppliers of artificial intelligence (AI) market in India.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Anatomic Pathology Market

Posted by fidest press agency su martedì, 20 agosto 2019

The global anatomic pathology market is projected to attain a size of $24.3 billion by 2024, progressing at a 5.8% CAGR during the forecast period.
The increasing prevalence of chronic diseases, developments in technology, and surging geriatric population are some of the major reasons behind the growth of the market. On the basis of application, the market is categorized into drug discovery, disease diagnosis, and others. Out of these, the disease diagnosis category is expected to hold the largest share of more than 65.0% in the market by 2024. This is attributed to the surging aging population and rising number of patients suffering from the chronic ailments. When segmented by end user, the anatomic pathology market is classified into diagnostic laboratories, ambulatory surgical centers, hospitals and clinics, and academic and research organizations. Among these, in 2018, diagnostic laboratories led the market with a share of 45.8%, followed by hospitals and clinics that held a 31.4% share. The reason behind this is that these laboratories are less expensive as compared to hospitals and clinics.The Asia-Pacific (APAC) anatomic pathology market is predicted to witness the fastest growth at a 6.7% CAGR during the forecast period. The key factors responsible for such rapid progress would be the acceptance of personalized medicine, growing number of chronic ailment patients, increasing investment in diagnostic research by non-government and government organizations, and entry of established players in the region. The increasing entrance rate of international players in the market is helping in better availability of advanced and innovative anatomic pathology consumables and instruments in APAC.For instance, in January 2019, Nichirei Bioscience (one of the leading suppliers of diagnostic and biological products in Japan) collaborated with Biocartis Group NV for the product registration and exclusive distribution of molecular diagnostic (MDx) oncology tests, developed by Biocartis, in Japan, which work on the sample-to-result Idylla platform, which is fully automated, Under this, Nichirei Bioscience agreed to get the regulatory approval of the Japanese Ministry of Health, Labour, and Welfare for Idylla MDx oncology tests. After the registration, Nichirei Bioscience aims to provide Biocartis’ Idylla platform to 2,000 pathology laboratories within its commercial network in Japan.
The key players operating in the anatomic pathology market are gearing up to introduce innovative solutions to improve their market presence. For instance, in February 2019, Quest Diagnostics Inc., a U.S.-based diagnostic information services provider, purchased the clinical laboratory services unit of Boyce & Bynum Pathology Laboratories (BBPL), a leading supplier of diagnostic and clinical laboratory services in the Midwest. The acquisition is aimed at offering a larger portfolio of anatomic pathology and innovative clinical laboratory services to providers and patients throughout the region.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

7th International Conference on Bioimaging

Posted by fidest press agency su martedì, 20 agosto 2019

Valletta, Malta – February 24-26, 2020 Bioimaging is a term that covers the complex chain of acquiring, processing and visualizing structural or functional images of living objects or systems, including extraction and processing of image-related information. Examples of image modalities used in bioimaging are many, including X-ray, CT, MRI and fMRI, PET and HRRT PET, SPECT, MEG and so on.Medical imaging and microscope/fluorescence image processing are important parts of bioimaging referring to the techniques and processes used to create images of the human body, anatomical areas, tissues, and so on, down to the molecular level, for clinical purposes, seeking to reveal, diagnose, or examine diseases, or medical science, including the study of normal anatomy and physiology. Both classic image processing methods (e.g. denoising, segmentation, deconvolution and registration methods, feature recognition and classification) and modern machine, in particular, deep, learning techniques represent an indispensable part of bioimaging, as well as related data analysis and statistical tools.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

FINEOS lists on the Australian Securities Exchange

Posted by fidest press agency su martedì, 20 agosto 2019

FINEOS Corporation Holdings plc (ASX:FCL), a leading provider of group and individual core systems for life, accident and health insurance, today announced the commencement of trading on the Australian Securities Exchange (ASX) via an initial public offering (IPO). The total number of securities (CHESS Depository Interests or “CDIs”) on offer was 84.4 million at a price of A$2.50 per CDI. Total gross proceeds from the offer amounted to A$211 million.
FINEOS intends to use the net proceeds from the IPO to invest further in R&D to grow the FINEOS product footprint and develop new business lines, to invest in additional sales, marketing and client account management capabilities and to pay down existing debt and shareholders selling down.Key areas of growth strategy for FINEOS include:
• Increase our product penetration and introduce new products within the existing client base;
• Maintain technology leadership and continued product innovation of the entire FINEOS Platform.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain

Posted by fidest press agency su martedì, 20 agosto 2019

Basel. Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The FDA has also granted accelerated approval to Rozlytrek for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. These approvals are based on results from the integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials, and data from the Phase I/II STARTRK-NG study. In the integrated analysis, Rozlytrek was studied in several solid tumour types, including breast, cholangiocarcinoma, colorectal, gynaecological, neuroendocrine, non-small cell lung, salivary gland, pancreatic, sarcoma and thyroid cancers. In ROS1-positive, metastatic NSCLC, Rozlytrek shrank tumours in 78% of people with the disease (overall response rate [ORR]; N=51) and the duration of response (DoR) ranged from 1.8 to 36.8+ months (N=40 out of 51).1 Rozlytrek also shrank tumours in more than half of people with NTRK gene fusion-positive, locally advanced or metastatic solid tumours (ORR=57%; N=54), and objective responses were observed across 10 tumour types (DoR ranged from 2.8 to 26.0+ months; N=31 out of 54).1 Objective responses to Rozlytrek were seen in people with central nervous system (CNS) metastases at baseline.
The most common adverse reactions (≥20 percent) with Rozlytrek were fatigue, constipation, altered sense of taste (dysgeusia), swelling (oedema), dizziness, diarrhoea, nausea, nervous system disorders (dysaesthesia), shortness of breath (dyspnoea), muscle pain (myalgia), cognitive impairment, increased weight, cough, vomiting, fever (pyrexia), joint pain (arthralgia) and vision disorders. The FDA’s Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.2 The accelerated approval for NTRK gene fusion-positive solid tumors is based on tumour response rate and durability of response, and continued approval may be contingent upon verification and description of clinical benefit in the confirmatory trials.Biomarker testing for ROS1 in NSCLC and NTRK gene fusions across all solid tumours is the only way to identify people who are eligible for treatment with Rozlytrek. Roche is leveraging its expertise in developing personalised medicines and advanced diagnostics, in conjunction with Foundation Medicine, to help identify people with ROS1 and NTRK gene fusions. Foundation Medicine will submit FoundationOne®CDx to the FDA for approval as a companion diagnostic for Rozlytrek. An FDA-approved companion diagnostic for Rozlytrek is not available at this time.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

90th Anniversary of Listing on the New York Stock Exchange

Posted by fidest press agency su lunedì, 19 agosto 2019

Curtiss-Wright Corporation (NYSE: CW) will commemorate the 90th anniversary of its listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell® on Friday, August 23 at 4:00 p.m. EDT. The Company began trading on the NYSE on August 22, 1929. In recognition of this milestone, Chairman and Chief Executive Officer David C. Adams will ring the NYSE Closing Bell®, accompanied by members of the leadership team, executives and guests.“We are honored to be the 56th longest continuously listed company on the New York Stock Exchange and excited to celebrate our rich and distinctive history by ringing The Closing Bell®,” said Adams.Curtiss-Wright‘s legacy of innovation began with the earliest pioneers of the aviation industry. As a result of their successes, Curtiss-Wright was formed on July 5, 1929, by the merger of companies founded by Glenn Curtiss, the father of naval aviation, and the Wright brothers, renowned for history’s first flight.The event will be webcast live via the Internet on Livestream beginning at 3:56 p.m. EDT via https://www.nyse.com/bell.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis

Posted by fidest press agency su lunedì, 19 agosto 2019

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA).“We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences.The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievement of low disease activity and remission, and inhibition of structural damage for different sub-populations of patients living with RA. Across the FINCH program, safety data were consistent with previously reported results.“We are very happy with the validation of the filgotinib MAA by the EMA, as this represents the latest step forward in our partnership with Gilead to bring filgotinib as a new treatment option to RA patients across Europe,” said Dr. Walid Abi-Saab, Chief Medical Officer at Galapagos.The filgotinib filing will be reviewed by the EMA under the centralized licensing procedure for all 28 member states of the European Union, as well as Norway, Iceland and Liechtenstein. In early July, Gilead announced plans to submit a New Drug Application (NDA) for filgotinib for the treatment of RA in the United States before the end of the year.Filgotinib is an investigational agent and is not approved anywhere globally. Its efficacy and safety have not been established by any regulatory authorities.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Cubic to Deliver CBRND Collective Training Simulation System for Australian Army

Posted by fidest press agency su lunedì, 19 agosto 2019

Cubic Corporation (NYSE: CUB) today announced Cubic Defence New Zealand, which operates within its Cubic Global Defense business division, was selected to deliver a new simulation-enabled collective training capability, to better prepare soldiers for chemical, biological, radiological or nuclear defense (CBRND) missions. The capability will be delivered jointly by Cubic Defence Australia and New Zealand, expanding the offering for the Australian Army Combat Training Centre based in Townsville, North Queensland. The Cubic-developed CBRND training sub-system employs simulated CBRN threats projected within a synthetic environment to live instrumented soldiers in the exercise environment. “Cubic’s capability includes simulation of detection, casualty status, treatment and weather impacts,” said Miles Macdonald, general manager of Cubic Defence Australia and New Zealand. “The system is capable of projecting synthetic CBRN effects over large numbers of soldiers exercising on Australia’s training areas, enabling highly realistic scenarios to be exercised under simulated battlefield conditions.” “This training capability allows commanders and their units to experience the tactical and logistical impacts of operations in a CBRN threat environment,” added Macdonald. “It’s about enabling soldiers to realistically undertake threat identification, to test their mitigation and decontamination procedures and to understand the consequence of a threat and their own actions within the safety of a training environment.” The capability will be incorporated to the training activities available through the Combat Training Centre. Cubic is the market leader in providing live instrumented training capability to armed forces globally. Its training systems replicate the combat environment, allowing performance assessment and development of units and their commanders.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Fostering Cultural Transformation in Healthcare, Education and Economic Empowerment

Posted by fidest press agency su lunedì, 19 agosto 2019

Experts at identifying opportunities to improve the human condition in a significant way, Thought Leadership & Innovation Foundation (TLI) announces the release of its white paper, “Engineering Cultural Change for Community Health Improvement.” Authored by Bill Oldham, founder and chairman of the Board, TLI, the paper highlights the value of TLI’s innovative, collaborative approach to helping communities across the country that are struggling to come up with a coordinated, cohesive set of actions to effect change and generate social capital for the common good.“TLI takes a deeply human-centered strategy, designed to empower individuals while tackling complex social problems and nurturing innovation,” says Oldham. “It requires seeing the world in a new light and forging the most optimal partnerships to avoid changes that are simply cosmetic or ineffective. Even the largest and highest profile organizations, municipalities, academic institutions and other entities need help to amplify and augment existing programs, using new methods and technologies where they add value.”TLI engages leaders from all business and academic sectors, inviting them to share their stories, ideas and innovation – moving them from dialogue to vision and action – by managing the engagement and interaction of stakeholders, analyzing critical data, synthesizing data for decisions, tracking outcomes and measuring results.The white paper features several case studies showcasing TLI’s role in a number of impactful projects aimed at bettering lives, communities and the nation as a whole across a number of areas, including infectious determinants of chronic diseases, the opioid epidemic, technological innovation, clinical healthcare workflow, human performance measurement and outcomes metrics, using data analytics to determine the quality of medical care patients receive, and economic empowerment through education.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

AM Best Downgrades Credit Ratings of Westminster American Insurance Company

Posted by fidest press agency su lunedì, 19 agosto 2019

AM Best has downgraded the Financial Strength Rating to A- (Excellent) from A (Excellent) and the Long-Term Issuer Credit Rating to “a-” from “a” of Westminster American Insurance Company (Westminster) (Owings Mills, MD). The outlook of these Credit Ratings (ratings) remains stable.The ratings reflect Westminster’s balance sheet strength, which AM Best categorizes as strong, as well as its strong operating performance, limited business profile and appropriate enterprise risk management (ERM).The rating downgrades reflect the significant level of adverse loss reserve development Westminster has reported recently, which has led to a steady decline in the company’s operating performance. The adverse reserve development added 12.3 and 6.9 points, respectively, to the 2017 and 2018 combined ratios. In response, management has taken aggressive actions through a comprehensive claims audit, which has resulted in additional case reserve strengthening, specifically on liability claims, through second-quarter 2019. Going forward, the company has implemented a much more conservative approach when establishing initial loss reserves for all liability claims, which should lessen adverse reserve development. As a result, AM Best anticipates that future operating performance will remain strong as the company continues to grow and expand, but the company will not achieve past levels of performance.The stable outlooks reflect AM Best’s expectation that Westminster will maintain its strong balance sheet strength and operating performance, and that the recent corrective measures taken by management will meaningfully improve the company’s overall ERM effectiveness. Westminster’s overall risk-adjusted capitalization remains supportive of its strong balance sheet strength assessment, and the company continues to maintain a conservative investment portfolio. Although recent adverse reserve development has dampened Westminster’s underwriting profitability, the company has continued to achieve underwriting and pre-tax operating profits, as well as surplus growth.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

10th Annual Donation and Transplantation Symposium

Posted by fidest press agency su lunedì, 19 agosto 2019

Registration is now open for the nation’s largest Donation and Transplantation Symposium to be held Tuesday, Oct. 22, at the Sheraton Fairplex Hotel and Convention Center in Pomona, California. Sponsored by OneLegacy, this 10th annual gathering is expected to attract more than 1,000 hospital and transplant professionals who will share best practices designed to positively impact organ and tissue donation activity in their own hospitals and communities.Topics to be discussed include the role of hospitals in the donation process, patient rights, community collaboration, the diagnosis of brain death, dealing with surgical delays and new innovations in tissue donation. Physicians, nurses, transplant center staffs, pastoral care professionals, palliative care professionals and social workers are among those expected to attend.“Organ and tissue donation is an incredible gift,” said Tom Mone, chief executive officer of OneLegacy, the largest organ, eye and tissue recovery organization in the world. “For 10 years this symposium has brought together health care professionals to share tools, information and innovations with the goal of saving more lives through organ and tissue donation as well as helping donor families find comfort and peace throughout the donation process.” OneLegacy achieved a record-setting performance in lives saved in 2018, with 1,519 lifesaving organ transplants, surpassing the previous mark set just a year earlier. In addition, OneLegacy fulfilled 2,893 individuals’ wishes to be tissue donors, which resulted in more than 150,000 tissues transplanted.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Treatment of Irritable Bowel Syndrome with Constipation

Posted by fidest press agency su lunedì, 19 agosto 2019

Alfasigma USA, Inc. today announced that ZELNORM™ (tegaserod) is now available in the United States as a prescription pharmaceutical treatment for irritable bowel syndrome with constipation (IBS-C) in adult women less than 65 years of age. Alfasigma USA acquired ZELNORM from Sloan Pharma S.à r.l., a subsidiary of US WorldMeds Holdings, LLC, in July 2019.“We are pleased to inform U.S. physicians and pharmacists about the reintroduction of ZELNORM and how Alfasigma USA is supporting the availability, access to, and appropriate use of this important medicine for the many patients who cope daily with an urgent need for new treatment options,” said Bryan Downey, president and chief executive officer at Alfasigma USA. “Our growing U.S. organization and national sales force is excited to lead the return of ZELNORM and committed to making a positive difference in the lives of patients.”
Originally approved in 2002 as the first prescription medication for IBS-C, ZELNORM was voluntarily withdrawn from the market in 2007 due to concerns regarding possible cardiovascular risk. In March 2019, ZELNORM was approved for reintroduction in the U.S. for use in adult women under 65 years of age with IBS-C, following a thorough safety review by the FDA and an FDA-assembled Gastrointestinal Drugs Advisory Committee (GIDAC). The evaluation consisted of a review of clinical data from 29 placebo-controlled trials and post-marketing treatment outcome data.
ZELNORM is the only serotonin-4 (5-HT4) receptor agonist approved to treat IBS-C. It targets the 5-HT4 receptor at multiple neurons (sensory, motor, secretory motor) and smooth muscle cells in the gastrointestinal tract to induce contraction and relaxation, and decrease pain signaling.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

United States E-Cigarette Market Analysis Package

Posted by fidest press agency su lunedì, 19 agosto 2019

This report explores consumer e-liquid preferences, choices and behaviours based on a consumer survey conducted in December 2018, respondents were members of the Consumer Advocates for Smoke-free Alternatives Association (CASAA). Gain insight into key consumer data from 3-year tracking and analysis of consumer behaviours. The author explores the demographics of low, medium and high nicotine users, as well as their brand and product usage and preferences.Between 2018 and 2019 there was a significant increase in closed system products available from US online retailers, mainly pre-filled tank/pod systems which showed a fall in average price. This research will enable you to understand which closed system products were prevalent online in the US, which brands, products and flavours were the most common, and the increase/decrease of products in the period between Q1 2018 to Q1 2019.From experience in tracking the specialist vape store and online vape retailer channels, the author realised that there is a gap in understanding the market for specific outlets which sell tobacco and smoking-related products but are not specialists in vaping products nor represented in widely quoted data. This report explores how vaping products fare in smoke and head shops across the US, including the number of these stores, best selling brands, customer visits and our future predictions.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The “Biopharmaceutical Fermentation Systems Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025”

Posted by fidest press agency su lunedì, 19 agosto 2019

The report predicts the global biopharmaceutical fermentation systems market to grow with a CAGR of 5.8% over the forecast period from 2019-2025.The report on the global biopharmaceutical fermentation systems market provides qualitative and quantitative analysis for the period from 2017 to 2025. The study on biopharmaceutical fermentation systems market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.The report on biopharmaceutical fermentation systems market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global biopharmaceutical fermentation systems market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.Porter’s five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global biopharmaceutical fermentation systems market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »